Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

Elhalawani, Hesham; Abdel‐Rahman, Omar

doi:10.2147/tcrm.s71045

Cited by 2 publications

(1 citation statement)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peritoneal carcinomatosis (PC) arising from gastric/gastroesophageal junction cancer (GC) presents a complex and challenging clinical scenario, with devastating manifestations of intestinal inflammation, obstruction, and nutritional compromise. Outcomes are uniformly poor in afflicted patients, and there is an urgent need for innovative approaches to address the unique patient care challenges it poses [1,2]. Although PC can arise from any number of primary tumor types, immunotherapy is of special interest in gastric cancer peritoneal carcinomatosis (GC-PC), given the rapid integration of immune checkpoint inhibition into the care of patients with GC.…”

Section: Introductionmentioning

confidence: 99%

Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment

Lewis,

Dadgar,

Yellin

et al. 2023

Cancers

View full text Add to dashboard Cite

Peritoneal carcinomatosis originating from gastric/gastroesophageal junction cancer (GC-PC) occurs in a defined subset of gastric cancer patients with unique clinical, pathologic, molecular and immunologic characteristics that create significant obstacles to effective treatment with modern therapy. Although systemic chemo- and immuno- therapy have yielded disappointing results in GC-PC, recent advances in the characterization of GC-PC and peritoneal immune biology present new opportunities for targeted therapeutics. In this review article, we discuss the distinct properties of GC-PC and the peritoneal immune environment as they pertain to current and investigative treatment strategies. We discuss pre-clinical studies and clinical trials relevant to the modulation of the peritoneal environment as a therapeutic intervention in GC-PC. Finally, we present a road map for future combinatorial strategies based on the conception of the peritoneal cavity as a bioreactor. Within this isolated compartment, prevailing immunosuppressive conditions can be altered through regional interventions toward an adaptive phenotype that would support the effectiveness of regionally delivered cellular therapy products. It is hoped that novel combination strategies would promote efficacy not only in the sequestered peritoneal environment, but also via migration into the circulation of tumor-reactive lymphocytes to produce durable systemic disease control, thereby improving oncologic outcome and quality of life in patients with GC-PC.

show abstract

Section: Introductionmentioning

confidence: 99%

Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment

Lewis,

Dadgar,

Yellin

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature

Matboli¹,

El‐Nakeep²,

Hossam³

et al. 2016

WJG

View full text Add to dashboard Cite

Gastric cancer (GC) is a global health problem and a major cause of cancer-related death with high recurrence rates ranging from 25% to 40% for GC patients staging II-IV. Unfortunately, while the majority of GC patients usually present with advanced tumor stage; there is still limited evidence-based therapeutic options. Current approach to GC management consists mainly of; endoscopy followed by, gastrectomy and chemotherapy or chemo-radiotherapy. Recent studies in GC have confirmed that it is a heterogeneous disease. Many molecular characterization studies have been performed in GC. Recent discoveries of the molecular pathways underlying the disease have opened the door to more personalized treatment and better predictable outcome. The identification of molecular markers is a useful tool for clinical managementin GC patients, assisting in diagnosis, evaluation of response to treatment and development of novel therapeutic modalities. While chemotherapeutic agents have certain physiological effects on the tumor cells, the prediction of the response is different from one type of tumor to the other. The specificity of molecular biomarkers is a principal feature driving their application in anticancer therapies. Here we are trying to focus on the role of molecular pathways of GC and well-established molecular markers that can guide the therapeutic management.

show abstract

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

Cited by 2 publications

References 66 publications

Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment

Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment

Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature

Contact Info

Product

Resources

About